RVX_logo_RGB.jpg
Resverlogix Publishes New Data Highlighting Apabetalone’s Benefit in Non-alcoholic Fatty Liver Disease
22 août 2022 07h12 HE | Resverlogix Corp
CALGARY, Alberta, Aug. 22, 2022 (GLOBE NEWSWIRE) -- Resverlogix Corp. ("Resverlogix") (TSX:RVX) today announced the publication of an article entitled “Reduction in the Risk of Major Adverse...
Resverlogix commences dosing of patients in Phase 2b COVID-19 study
Resverlogix Announces Commencement of Patient Enrollment and Dosing in a Phase 2b Trial for a Promising Canadian-Developed COVID-19 Treatment
18 janv. 2022 07h15 HE | Resverlogix Corp
CALGARY, Alberta, Jan. 18, 2022 (GLOBE NEWSWIRE) -- Resverlogix Corp. ("Resverlogix") (TSX:RVX) is pleased to announce today that enrollment and dosing of patients has commenced in a Phase 2b study...